JO25567: common adverse events reported in the safety population (1/3)1
![Image 27@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2027@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2027@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2027@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Data are n (%). Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 3–5
JO25567: common adverse events reported in the safety population (2/3)1
![Image 28@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2028@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2028@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2028@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Data are n (%). Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 3–5
JO25567: common adverse events reported in the safety population (3/3)1
![Image 29@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2029@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2029@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/erlotinib-plus-bevacizumab-combination-studies/jo25567-phase-ii-trial/Image%2029@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Data are n (%). Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 3–5